Indivior, Inc. has agreed to pay $10 million to settle Federal Trade Commission charges that it violated antitrust laws through a deceptive scheme to thwart lower priced generic competition with its branded opioid replacement therapy drug Suboxone. The proposed stipulated order for a permanent injunction and equitable monetary relief also bars Indivior from similar future conduct. […]